Terminated PHASE2 INTERVENTIONAL 1-arm NCT00760461

Domperidone in Refractory Gastroparesis

Sponsor: Yale University

Interventions Domperidone

Updated 9 times since 2017 Last updated: Aug 17, 2017 Started: Oct 31, 2008 Primary completion: Jul 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Enrolled subjects were unable to receive drug from dispensing pharmacy.

Other terminated trials from Yale University

See all terminations from Yale University

This PHASE2 trial investigates Gastroparesis and is currently terminated or withdrawn. Yale University leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Sep 2017 — Jun 2018 [monthly]

Terminated PHASE2
Feb 2017 — Sep 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States